ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed
15.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 191 citations in OpenAlex.
- Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.ESMO open · 2022Trial
- Envonalkib Versus Crizotinib in Treatment-NaiveMedComm · 2026Article
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Article
- A new chapter in targeting kinase enzymes in cancer.Nature · 2026Article
- Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion.Cancer metastasis reviews · 2026Review
- Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2026Review
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.Respiratory research · 2026Article
- [Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Acquired resistance of cancer therapies: Mechanisms and perspectives.Chinese medical journal · 2026Review
- Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.Current oncology (Toronto, Ont.) · 2026Article
- Short-term response to alectinib and rapid progression in a lung squamous cell carcinoma patient harboring anTranslational cancer research · 2026Article
- Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Review
- A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.Genome biology · 2026Article
- Exploratory Identification of Gene Copy Number Cut-Off for NGS-BasedLung Cancer (Auckland, N.Z.) · 2026Article
- AcquiredFrontiers in oncology · 2026Article
- The role of m6A modification in non-small cell lung cancer: functional insights and impact on therapy resistance.Cancer cell international · 2025Review
- Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Biochemical Society transactions · 2025Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Ibiayi Dagogo-Jack *Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Satoshi Yoda *Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-4201-1392
Jochen K LennerzDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-2434-4978
Adam LangenbucherMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Jessica J LinMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-7373-3916
Marguerite M RooneyMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Kylie Prutisto-ChangMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Audris OhMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Nathaniel A AdamsMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Beow Y YeapMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Emily ChinMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Andrew DoMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-5782-5818
Hetal D MarbleDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts.
Sara E StevensMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Subba R DigumarthyDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-4041-6716
Ashish SaxenaDepartment of Medicine, Weill Cornell Medicine, New York, New York.
Rebecca J NagyGuardant Health, Inc., Redwood City, California.
Cyril H BenesMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-8751-9707
Christopher G AzzoliMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Michael S LawrenceMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Justin F GainorMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Alice T Shaw *Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. ashaw1@partners.org ahata@mgh.harvard.edu.
Aaron N Hata *Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. ashaw1@partners.org ahata@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · USCornell University · USGuardant (United States) · US
Funding
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MTraining Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6MModeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MOvercoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, Jessica Jiyeong Lin · 2012 to 2026
$5.5MIlluminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0MNCI NIH HHS K12 CA087723NCI NIH HHS R01 CA129933NCI NIH HHS R01 CA164273NCI NIH HHS R37 CA225655NCI NIH HHS T32 CA071345
Abstract
purposeMost EXPERIMENTAL
designWe performed FISH and/or next-generation sequencing on 207 posttreatment tissue (
results
conclusionsTreatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired
Indexed as
Gene AmplificationAminopyridinesAnaplastic Lymphoma KinaseBiomarkers, TumorCarcinoma, Non-Small-Cell LungCrizotinibDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansLactamsLactams, MacrocyclicLung NeoplasmsPrognosisProtein Kinase InhibitorsProto-Oncogene Proteins c-metALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseBiomarkers, TumorCrizotinibLactamsLactams, MacrocycliclorlatinibMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyrazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.